0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Interim Recommendations for the Use of Haemophilus influenzae Type b (Hib) Conjugate Vaccines Related to the Recall of Certain Lots of Hib-Containing Vaccines (PedvaxHIB® and Comvax®) FREE

JAMA. 2008;299(8):893-894. doi:10.1001/jama.299.8.893.
Text Size: A A A
Published online

MMWR. 2007;56:1318-1320

On December 19, this report was posted as an MMWR Dispatch on the MMWR website (http://www.cdc.gov/mmwr).

On December 13, 2007, Merck & Co., Inc. (West Point, Pennsylvania) announced a voluntary recall of certain lots of two Haemophilus influenzae type b (Hib) conjugate vaccines, PedvaxHIB® (monovalent Hib vaccine) and Comvax® (Hib/hepatitis B vaccine). Providers should return unused vaccine from these recalled lots using procedures outlined on the Merck website at http://www.merckvaccines.com/PCHRecall.pdf. Additional information regarding the affected lots is available online from the Food and Drug Administration (FDA) at http://www.fda.gov/consumer/updates/hib121307.html. Merck has suspended production of its Hib conjugate vaccines and does not expect to resume distribution of these vaccines until the fourth quarter of 2008. The recall of PedvaxHIB and Comvax and suspension of production are expected to result in short-term disruption to the Hib vaccine supply in the United States.

Merck issued this voluntary recall as a precautionary measure because the company cannot assure the sterility of equipment used during manufacture of these lots. However, the potency of the vaccine in the recalled lots was not affected, and Merck reported that no contamination of vaccine has been detected. Therefore, children who received Hib conjugate vaccine from the recalled lots do not need revaccination or any special follow-up.

Two other Hib conjugate vaccines manufactured by Sanofi Pasteur (Swiftwater, Pennsylvania) and currently licensed and available for use in the United States, ActHIB® (monovalent Hib vaccine) and TriHIBit® (diphtheria and tetanus toxoids and acellular pertussis [DTaP]/Hib vaccine), are unaffected by the recall. However, Sanofi Pasteur likely will not be able to immediately provide adequate Hib vaccine to vaccinate fully all children for whom the vaccine is recommended.1

The recommended vaccination schedule for all available Hib-containing vaccines consists of a primary series (consisting of 2 or 3 doses, depending on the formulation) administered beginning at age 2 months and a booster dose at age 12-15 months.1 Because of the short-term reduction in available doses of Hib-containing vaccines, CDC, in consultation with the Advisory Committee on Immunization Practices (ACIP), the American Academy of Family Physicians, and the American Academy of Pediatrics, recommends that providers temporarily defer administering the routine Hib vaccine booster dose administered at age 12-15 months except to children in specific groups at high risk, which are described in this report. Providers should register and track children for whom the booster dose is deferred to facilitate recalling them for vaccination when supply improves.

Sustained high levels of coverage with Hib conjugate vaccine have resulted in a substantial decline in the incidence of Hib disease in the United States.2 In 2006, the incidence of Hib disease in children aged <5 years was 0.21 per 100,000, representing a greater than 99% reduction in disease compared with incidence in the prevaccine era.3 Population immunity is a result of direct protection of children by vaccination with Hib vaccine and herd immunity resulting from prevention of nasopharyngeal carriage and interruption of Hib transmission.4 Short-term deferral of the booster dose among children aged 12-15 months is not likely to result in an increased risk for Hib disease because of continued protection of children with the primary series and the low level of nasopharyngeal carriage and transmission achieved in the United States by the Hib immunization program.

The vaccines affected by the recall, PedvaxHIB and Comvax, contain Hib capsular polysaccharide (i.e., polyribosylribitol phosphate [PRP]) covalently linked to a meningococcal outer membrane protein (OMP) carrier. The two unaffected vaccines, ActHIB and TriHIBit, are PRP-tetanus toxoid (PRP-TT) conjugate Hib vaccines. PedvaxHIB and Comvax are recommended as a 2-dose primary series (at ages 2 and 4 months), whereas ActHIB is recommended as a 3-dose primary series (at ages 2, 4, and 6 months). ActHIB and PedvaxHIB also are licensed for the 12-15 month booster dose. TriHIBit is licensed only for the 12-15 month booster dose. Children who are not at increased risk for Hib disease, as described in this report, and who received PRP-OMP vaccines for only the first or second dose of their routine primary series may be administered PRP-TT to complete the primary series. In these children, a total of 3 doses will complete the primary series. Children who are behind schedule should complete the primary series according to age-appropriate recommendations.1

Certain children are at increased risk for Hib disease, including children with asplenia, sickle cell disease, human immunodeficiency virus infection and certain other immunodeficiency syndromes, and malignant neoplasms.5 CDC recommends that providers continue to vaccinate these children with available Hib conjugate vaccines according to the routinely recommended schedules, including the 12-15 month booster dose. PedvaxHIB (if available), ActHIB, and TriHIBit may be used for the booster doses for these children during this shortage. Hib vaccines also are recommended for use in prophylaxis for susceptible close contacts of patients with Hib disease. CDC recommends that providers continue to vaccinate close contacts according to published guidelines.5

American Indian/Alaska Native (AI/AN) children also are at increased risk for Hib disease, particularly in the first 6 months of life.5 Before the use of Hib conjugate vaccines, the incidence of Hib disease among young AI/AN children in AI/AN communities was approximately 10 times higher than among children of comparable age in the general population.5 Compared with PRP-TT conjugate vaccines, the administration of PRP-OMP vaccines leads to a more rapid seroconversion to protective antibody concentrations within the first 6 months of life.6,7 Failure to use PRP-OMP vaccines for the first dose is associated with excess cases of Hib disease in AI/AN infants living in communities where Hib transmission is ongoing and exposure to colonized persons is likely.8 Although PRP-OMP and PRP-TT vaccines are equally effective after completion of the primary series, availability of more than one Hib vaccine in a clinic could lead to administration of the wrong vaccine for the first dose in these populations.5 For these reasons, CDC recommends that providers who currently use PRP-OMP–containing Hib vaccines (PedvaxHIB and Comvax) to serve predominantly AI/AN children in AI/AN communities continue to stock and use only PRP-OMP– containing Hib vaccines not affected by the recall and vaccinate according to the routinely recommended schedules, including the 12-15 month booster dose. In its vaccine stockpile, CDC has PRP-OMP–containing Hib vaccines not affected by the recall and will prioritize distribution of available PRP-OMP vaccines for use in AI/AN communities. AI/AN children not in AI/AN communities or who already receive PRP-TT conjugate vaccines should continue to be vaccinated with available vaccines according to the routinely recommended schedules, including the 12-15 month booster dose.

Limitations of the vaccine supply underscore the importance of surveillance for Hib disease in children and serotyping of H. influenzae isolates. ACIP recommends that public health practitioners conduct thorough and timely investigations of all cases of Hib disease. To maximize the amount of available vaccine, providers should order only the number of doses of vaccine required to meet immediate needs (i.e., a supply for up to 4 weeks) and should refrain from attempting to build an inventory of Hib vaccine. CDC, ACIP, and other partners will continue to monitor the supply of available Hib vaccines and the epidemiology of Hib disease and provide updates when available. FDA and CDC will continue to monitor the safety of Hib vaccines. Any adverse events that are potentially vaccine-related should be reported to the Vaccine Adverse Event Reporting System (VAERS) by telephone (800-822-7967) or online (http://www.vaers.hhs.gov). Additional information regarding Hib vaccine is available at http://www.cdc.gov/vaccines/vpd-vac/hib/default.htm. Updates on vaccine supply are available at http://www.cdc.gov/vaccines/vac-gen/shortages/default.htm#chart.

REFERENCES

CDC.  Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the ACIP.  MMWR. 1991;40:(No. RR-1) 
CDC.  Progress toward eliminating Haemophilus influenzae type b disease among infants and children—United States, 1987-1997.  MMWR Morb Mortal Wkly Rep. 1998;47(46):993-998
PubMed
CDC.  Active Bacterial Core surveillance report. Emerging Infections Program Network. Haemophilus influenzae, 2006 (provisional). Available at http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib06.pdf
Heath PT, McVernon J. The UK Hib vaccine experience.  Arch Dis Child. 2002;86(6):396-399
PubMed   |  Link to Article
Pickering LK, edRed book: 2006 report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: Academy of Pediatrics; 2006
Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type B conjugate vaccines in Alaska Native infants.  Pediatr Infect Dis J. 1993;12(6):484-492
PubMed   |  Link to Article
Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.  J Pediatr. 1992;120(2 Pt 1):184-189
PubMed   |  Link to Article
Lucher LA, Reeves M, Hennessy T,  et al.  Reemergence, in southwestern Alaska, of invasive Haemophilus influenzae type B disease due to strains indistinguishable from those isolated from vaccinated children.  J Infect Dis. 2002;186(7):958-965
PubMed   |  Link to Article

Figures

Tables

References

CDC.  Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b disease among infants and children two months of age and older. Recommendations of the ACIP.  MMWR. 1991;40:(No. RR-1) 
CDC.  Progress toward eliminating Haemophilus influenzae type b disease among infants and children—United States, 1987-1997.  MMWR Morb Mortal Wkly Rep. 1998;47(46):993-998
PubMed
CDC.  Active Bacterial Core surveillance report. Emerging Infections Program Network. Haemophilus influenzae, 2006 (provisional). Available at http://www.cdc.gov/ncidod/dbmd/abcs/survreports/hib06.pdf
Heath PT, McVernon J. The UK Hib vaccine experience.  Arch Dis Child. 2002;86(6):396-399
PubMed   |  Link to Article
Pickering LK, edRed book: 2006 report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: Academy of Pediatrics; 2006
Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type B conjugate vaccines in Alaska Native infants.  Pediatr Infect Dis J. 1993;12(6):484-492
PubMed   |  Link to Article
Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines.  J Pediatr. 1992;120(2 Pt 1):184-189
PubMed   |  Link to Article
Lucher LA, Reeves M, Hennessy T,  et al.  Reemergence, in southwestern Alaska, of invasive Haemophilus influenzae type B disease due to strains indistinguishable from those isolated from vaccinated children.  J Infect Dis. 2002;186(7):958-965
PubMed   |  Link to Article

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles